These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

377 related articles for article (PubMed ID: 33291312)

  • 21. Nanocarriers for oral delivery of biologics: small carriers for big payloads.
    Cao Y; Rewatkar P; Wang R; Hasnain SZ; Popat A; Kumeria T
    Trends Pharmacol Sci; 2021 Nov; 42(11):957-972. PubMed ID: 34593258
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Ionic liquids and deep eutectic solvents for the stabilization of biopharmaceuticals: A review.
    Veríssimo NVP; Mussagy CU; Bento HBS; Pereira JFB; Santos-Ebinuma VC
    Biotechnol Adv; 2024; 71():108316. PubMed ID: 38199490
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Insights on Development Aspects of Polymeric Nanocarriers: The Translation from Bench to Clinic.
    Tewari AK; Upadhyay SC; Kumar M; Pathak K; Kaushik D; Verma R; Bhatt S; Massoud EES; Rahman MH; Cavalu S
    Polymers (Basel); 2022 Aug; 14(17):. PubMed ID: 36080620
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Immune-Modulating Lipid Nanomaterials for the Delivery of Biopharmaceuticals.
    Kim S; Choi B; Kim Y; Shim G
    Pharmaceutics; 2023 Jun; 15(6):. PubMed ID: 37376208
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Protein crystals for the delivery of biopharmaceuticals.
    Basu SK; Govardhan CP; Jung CW; Margolin AL
    Expert Opin Biol Ther; 2004 Mar; 4(3):301-17. PubMed ID: 15006725
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Emerging delivery platforms for mucosal administration of biopharmaceuticals: a critical update on nasal, pulmonary and oral routes.
    Thwala LN; Préat V; Csaba NS
    Expert Opin Drug Deliv; 2017 Jan; 14(1):23-36. PubMed ID: 27351299
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Multifunctional and stimuli-responsive nanocarriers for targeted therapeutic delivery.
    Majumder J; Minko T
    Expert Opin Drug Deliv; 2021 Feb; 18(2):205-227. PubMed ID: 32969740
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Solid lipid nanocarriers in drug delivery: characterization and design.
    Mu H; Holm R
    Expert Opin Drug Deliv; 2018 Aug; 15(8):771-785. PubMed ID: 30064267
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Drying technology strategies for colon-targeted oral delivery of biopharmaceuticals.
    Vass P; Démuth B; Hirsch E; Nagy B; Andersen SK; Vigh T; Verreck G; Csontos I; Nagy ZK; Marosi G
    J Control Release; 2019 Feb; 296():162-178. PubMed ID: 30677436
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Interferon-Based Biopharmaceuticals: Overview on the Production, Purification, and Formulation.
    Castro LS; Lobo GS; Pereira P; Freire MG; Neves MC; Pedro AQ
    Vaccines (Basel); 2021 Apr; 9(4):. PubMed ID: 33915863
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Oral delivery of therapeutic peptides and proteins: Technology landscape of lipid-based nanocarriers.
    Haddadzadegan S; Dorkoosh F; Bernkop-Schnürch A
    Adv Drug Deliv Rev; 2022 Mar; 182():114097. PubMed ID: 34999121
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Plants as bioreactors for biopharmaceuticals: regulatory considerations.
    Miele L
    Trends Biotechnol; 1997 Feb; 15(2):45-50. PubMed ID: 9081298
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The Astonishing Accomplishment of Biological Drug Delivery using Lipid Nanoparticles: An Ubiquitous Review.
    Kapoor D; Chilkapalli SC; Prajapati BG; Rodriques P; Patel R; Singh S; Bhattacharya S
    Curr Pharm Biotechnol; 2024 Jan; ():. PubMed ID: 38265380
    [TBL] [Abstract][Full Text] [Related]  

  • 34. An Overview of the Stability and Delivery Challenges of Commercial Nucleic Acid Therapeutics.
    Ingle RG; Fang WJ
    Pharmaceutics; 2023 Apr; 15(4):. PubMed ID: 37111643
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Recent Advances in the Noninvasive Delivery of mRNA.
    Qin M; Du G; Sun X
    Acc Chem Res; 2021 Dec; 54(23):4262-4271. PubMed ID: 34756014
    [TBL] [Abstract][Full Text] [Related]  

  • 36. PASylation as a Powerful Technology for Improving the Pharmacokinetic Properties of Biopharmaceuticals.
    Ahmadpour S; Hosseinimehr SJ
    Curr Drug Deliv; 2018; 15(3):331-341. PubMed ID: 29165076
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Recent Biomedical Approaches for Chitosan Based Materials as Drug Delivery Nanocarriers.
    Iacob AT; Lupascu FG; Apotrosoaei M; Vasincu IM; Tauser RG; Lupascu D; Giusca SE; Caruntu ID; Profire L
    Pharmaceutics; 2021 Apr; 13(4):. PubMed ID: 33924046
    [TBL] [Abstract][Full Text] [Related]  

  • 38. License Compliance Issues For Biopharmaceuticals: Special Challenges For Negotiations Between Companies And Non-Profit Research Institutions.
    Ponzio TA; Feindt H; Ferguson S
    LES Nouv; 2011 Sep; 46(3):216-225. PubMed ID: 22162900
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Overcoming multiple gastrointestinal barriers by bilayer modified hollow mesoporous silica nanocarriers.
    Wang Y; Zhao Y; Cui Y; Zhao Q; Zhang Q; Musetti S; Kinghorn KA; Wang S
    Acta Biomater; 2018 Jan; 65():405-416. PubMed ID: 29037897
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Nanoparticles Functionalized with Venom-Derived Peptides and Toxins for Pharmaceutical Applications.
    Dos Santos AP; de Araújo TG; Rádis-Baptista G
    Curr Pharm Biotechnol; 2020; 21(2):97-109. PubMed ID: 31223083
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.